ROSE SHEA: Open Payments
NPI 1801511217 · BRIDGEPORT, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,616 in 194 payments from 13 companies in 2025. Trend: 2023 $946 · 2024 $2,987 · 2025 $4,616
Food & beverage: $4,393Education: $223
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 35 | $967 |
| E.R. Squibb & Sons, L.L.C. | 40 | $633 |
| ABBVIE INC. | 34 | $623 |
| Alkermes, Inc. | 19 | $503 |
| Otsuka America Pharmaceutical, Inc. | 15 | $471 |
| Teva Pharmaceuticals USA, Inc. | 12 | $437 |
| Axsome Therapeutics, Inc. | 3 | $260 |
| Neurocrine BioSciences, Inc. | 11 | $254 |
| Vanda Pharmaceuticals Inc. | 14 | $183 |
| Lundbeck LLC | 5 | $133 |
Products named: CAPLYTA, COBENFY, VRAYLAR, ARISTADA, REXULTI, Auvelity, INGREZZA, FANAPT.
Industry payments across CT — which companies pay providers there.
